NXP900
Phase 1bYES1-amplified Non-small cell lung cancer
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| NXP900 | YES1-amplified Non-small cell lung cancer | Phase 1b | Aug 31, 2026 | — |
| NXP200 (BRAF Inhibitor) | BRAF-Mutated Solid Tumors | Phase 1b | Oct 23, 2026 | — |
Upcoming milestones
YES1-amplified Non-small cell lung cancer
Data readoutCompany profile
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
BRAF-Mutated Solid Tumors
Data readout